Key Drivers
- Strong liquidity
- High R&D burn
- Negative profitability
AIAI Summary
Immatics now reads as a catalyst‑driven, binary biotech where a healthy cash runway materially reduces near‑term financing risk but investor returns hinge almost entirely on a few clinical readouts (SUPRAME, PRAME/IMA402) and their safety/efficacy outcomes.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High R&D burn
- •Negative profitability
IMTX has a strong, low‑leverage balance sheet providing runway, but persistent heavy R&D and operating losses create significant cash‑burn and valuation risk without further financing or clear clinical progress.
Price Behavior
Key Price Behavior Insights:
- •Downward bias
- •Near-term support
- •Weakened momentum
Over the last month the stock shows a modest downward bias—down ~6% from $10.06 to $9.43 with weakening momentum, nearby support at $9.24 and resistance around $10.30–$10.50, where holding above would be constructive while a decisive break below $9.24 would increase downside risk.
High of $10.50 on 2026-03-10 failed to sustain, signaling weakening upside
Sentiment & News
Key News Insights:
- •anzu-cel progress
- •PRAME/IMA402 upside
- •mid‑2026 catalyst
Immatics shows measurable anzu-cel progress in 2L melanoma and a deep cell‑therapy pipeline (PRAME, IMA402) but faces high investor expectations with a mid‑2026 SUPRAME interim readout as a pivotal yet unlikely near‑term stock mover.
Clinical progress supports long‑term upside but elevated valuation and a non‑definitive interim readout limit near‑term share movement
Similar Companies in Healthcare
Other companies in the same sector with AI ratings